相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。pH-Dependent 5-Aminosalicylates Releasing Preparations Do Not Affect Thiopurine Metabolism
Kenichiro Takahashi et al.
DIGESTION (2019)
Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis
Maya Olaisen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice
Sara van Gennep et al.
INFLAMMATORY BOWEL DISEASES (2018)
Evidence-based clinical practice guidelines for inflammatory bowel disease
Katsuyoshi Matsuoka et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
Haruhiko Ogata et al.
INTESTINAL RESEARCH (2018)
VARIANTS IN TPMT, ITPA, ABCC4 AND ABCB1 GENES AS PREDICTORS OF 6-MERCAPTOPURINE INDUCED TOXICITY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Goran Milosevic et al.
JOURNAL OF MEDICAL BIOCHEMISTRY (2018)
Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract
Alex Yu et al.
MOLECULAR PHARMACEUTICS (2017)
Development and validation of a reliable method for thiopurine methyltransferase (TPMT) enzyme activity in human whole blood by LC-MS/MS: An application for phenotypic and genotypic correlations
Supaporn Wiwattanakul et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2017)
MMX® technology and its applications in gastrointestinal diseases
Silvia Nardelli et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
Haruhiko Ogata et al.
INTESTINAL RESEARCH (2017)
Usefulness of mean corpuscular volume as a surrogate marker for monitoring thiopurine treatment in inflammatory bowel disease
Romein W. G. Dujardin et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2016)
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Yongjun Wang et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels
Adeyinka Abinusawa et al.
ADVANCES IN THERAPY (2015)
Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations
Alvaro Goyanes et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels
Srini Tenjarla
DRUGS IN R&D (2015)
A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia
Suk-Kyun Yang et al.
NATURE GENETICS (2014)
Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
Stephan Karl Bohm et al.
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2014)
Comparison of QD and TID Oral Mesalazine for Maintenance of Remission in Quiescent Ulcerative Colitis: A Double-blind, Double-dummy, Randomized Multicenter Study
Mamoru Watanabe et al.
INFLAMMATORY BOWEL DISEASES (2013)
5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis
Renata D'Inca et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Ulcerative colitis: prevention of relapse
Makoto Naganuma et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2013)
The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients
Xiang Gao et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Epidemiology and Natural History of Inflammatory Bowel Diseases
Jacques Cosnes et al.
GASTROENTEROLOGY (2011)
Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
Kara Bradford et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy
P. de Graaf et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Direct Comparison of Two Different Mesalamine Formulations for the Induction of Remission in Patients with Ulcerative Colitis: A Double-blind, Randomized Study
Hiroaki Ito et al.
INFLAMMATORY BOWEL DISEASES (2010)
Direct Comparison of Two Different Mesalamine Formulations for the Maintenance of Remission in Patients with Ulcerative Colitis: A Double-blind, Randomized Study
Hiroaki Ito et al.
INFLAMMATORY BOWEL DISEASES (2010)
Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis
J. P. Gisbert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Prevalence of ulcerative colitis and Crohn's disease in Japan
Keiko Asakura et al.
JOURNAL OF GASTROENTEROLOGY (2009)
Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease
Noritaka Takatsu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Analysis of Thiopurine S-Methyltransferase Genotypes in Japanese Patients with Inflammatory Bowel Disease
Hiromitsu Ban et al.
INTERNAL MEDICINE (2008)
Oral 5-ASA therapy in ulcerative colitis - What are the implications of the new formulations?
William J. Sandborn
JOURNAL OF CLINICAL GASTROENTEROLOGY (2008)
Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients
Takako Komiyama et al.
JOURNAL OF CROHNS & COLITIS (2008)
Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism
Nanne K. H. de Boer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Novel pathophysiological concepts of inflammatory bowel disease
T Hibi et al.
JOURNAL OF GASTROENTEROLOGY (2006)
6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease
MF Neurath et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2005)
Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease
RB Gearry et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Effects of aminosalicylates on thiopurine S-methyltransferase activity:: an ex vivo study in patients with inflammatory bowel disease
H Xin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation
M Brunner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis
WJ Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease:: impact of thiopurine S-methyltransferase polymorphism
M Schwab et al.
PHARMACOGENETICS (2002)
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
PW Lowry et al.
GUT (2001)
Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese
K Kumagai et al.
PHARMACOGENETICS (2001)
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2000)
分享论文
